trial · primary record
Placebo Matching Mitapivat
Non-Transfusion-dependent Alpha-Thalassemia
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 194 |
| Primary completion | 2028-12 |
| Primary endpoint | Double-Blind Period: Percentage of Participants Who Achieved Hemoglobin (Hb) Response From Week 12 Through Week 24 Compared With Baseline |
| Registry ID | NCT04770753 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:20.270Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04770753
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Placebo Matching Mitapivat · compound